Summary
Memantine (1-amino-3,5-dimethyladamantane) has previously been shown to attenuate or block chemically or electrically induced seizures in rodents at doses of 5–20 mg/kg i.p., suggesting that the drug might have potential utility in the treatment of seizures. In the present study, the effects of memantine were examined in amygdala-kindled and non-kindled rats. In fully kindled rats, i.e. a model of focal seizures with secondary generalization, memantine exerted no effects on seizure parameters at 5 mg/kg i.p., but reduced seizure severity and duration at 10 mg/kg. The threshold for induction of afterdischarges recorded from the amygdala was not altered after administration of 10 mg/kg. At 20 mg/kg, memantine induced spontaneous motor seizures in amygdala-kindled rats. No motor seizures were observed in non-kindled rats, but in both kindled and non-kindled animals memantine, 20 mg/kg, induced spikes in the electroencephalogram. Additional dose-dependent behavioural alterations observed after memantine included hyperactivity, ataxia and stereotypies, which may relate to the dopaminomimetic properties of the drug. The results demonstrate that kindled rats are more sensitive to central nervous system stimulating effects of memantine than non-kindled rats, which could relate to an impairment of inhibitory processes and/or alterations in synaptic transmission mediated by excitatory amino acids in the kindled brain.
Similar content being viewed by others
References
Bormann J (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166:591–592
Bowyer JF, Albertson TE (1982) The effects of pentylenetetrazol, bicuculline and strychnine on the development of kindled seizures. Neuropharmacology 21:985–990
Cain DP (1980) Effects of kindling or brain stimulation on pentylenetetrazol-induced convulsion susceptibility. Epilepsia 21:243–249
Fifková E, Marsala J (1967) Stereotaxic atlases for the cat, rabbit and rat. In: Bures J, Petran M, Zachar J (eds) Electrophysiological Methods in Biological Research. Academic Press, New York, pp 653–695
Fischer P-A, Jacobi B, Schneider E, Schönberger B (1977) Die Wirkung intravenöser Gaben von Memantin bei Parkinson-Kranken. Arzneimittelforschung 27:1487–1489
Franz DN (1985) Central nervous system stimulants. In: Goodman Gilman A, Goodman LS, Rail TW, Murad (eds) The Pharmacological Basis of Therapeutics, 7th edition. Macmillan Publishing Company, New York, pp 582–588
Freeman GF, Jarvis MF (1981) The effect of interstimulation interval on the assessment and stability of kindled seizure thresholds. Brain Res Bull 7:629–633
Grossmann A, Grossmann W, Jurna I (1976) The effect of dimethylaminoadamantane on neuronal membranes. Eur J Pharmacol 35:379–388
Grossmann W, Schütz W (1982) Memantin und neurogene Blasenstörungen im Rahmen spastischer Zustandsbilder. Arzneimittelforschung 32:1273–1276
Hayes BA, Balster RL (1985) Anticonvulsant properties of phencyclidine-like drugs in mice. Eur J Pharmacol 117:121–125
Kalichman MW (1982) Pharmacological investigations of convulsant γ-aminobutyric acid (GABA) antagonists in amygdalakindled rats. Epilepsia 23:163–171
Kamphuis W, Huisman E, Eadman WJ, Lopes da Silva FH (1989) Decrease in the GABA immunoreactivity and alteration of GABA metabolism after kindling in the rat hippocampus. Exp Brain Res 74:375–386
Klee MR (1982) Die Wirkung von Memantin auf Membraneigenschaften und postsynaptische Potentiale von Nervenzellen der Aplysia californica. Arzneimittelforschung 32:1259–1267
Kleinrok Z, Czuczwar SJ, Wojcik A, Przegalinski E (1978) Brain dopamine and seizure susceptibility in mice. Pol J Pharmacol Pharm 30:513–519
Kleinrok Z, Czuczwar SJ, Kozicka M (1980) Effect of dopaminergic and GABAergig drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice. Epilepsia 21:519–529
Klockgether T, Turski L, Schwartz M, Sontag K-H, Lehmenn J (1988) Paradoxical convulsant action of a novel non-competitive N-methyl-D-aspartate (NMDA) antagonist, tiletamine. Brain Res 461:343–348
Lloyd KG, Bossi L, Morselli PL, Munari C, Rougier M, Loiseau H (1986) Alterations of GABA-mediated synaptic transmission in human epilepsy. In: Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ (eds) Basic Mechanisms of the Epilepsies. Molecular and Cellular Approaches. Raven Press, New York p 1033–1044
Löscher W (1979) 3-Mercaptopropionic acid: convulsant properties, effects on enzymes of the γ-aminobutyrate system in mouse brain and antagonism by certain anticonvulsant drugs, aminooxyacetic acid and gabaculine. Biochem Pharmacol 28:1397–1407
Löscher W (1984) Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review. Methods Find Exp Clin Pharmacol 6:531–547
Löscher W (1989) GABA and the epilepsies. In: Bowery N (ed) GABA: From Basic Research to Clinical Applications. Pythagora Press, Rome p 260–300
Löscher W, Czuczwar SJ (1986) Studies on the involvement of dopamine D-1 and D-2 receptors in the anticonvulsant effect of dopamine agonists in various rodent models of epilepsy. Eur J Pharmacol 128:55–65
Löscher W, Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:145–181
Löscher W, Schwark WS (1985) Evidence for impaired GABAergic activity in the substantia nigra of amygdaloid kindled rats. Brain Res 339:146–150
Löscher W, Schwark WS (1987) Further evidence for abnormal GABAergic circuits in amygdala-kindled rats. Brain Res 420:385–390
Löscher W, Jäckel R, Czuczwar SJ (1986) Is amygdala kindling in rats a model for drug-resistant partial epilepsy? Exp Neurol 93:211–226
Macdonald RL, McLean MJ (1986) Anticonvulsant drugs: mechanisms of action. In: Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ (eds) Basic Mechanisms of the Epilepsies. Molecular and Cellular Approaches. Raven Press, New York, pp 713–736
Maj J (1982) Die Wirkung von Memantin auf zentrale Neurotransmittersysteme. Eine Zusammenfassung der Ergebnisse. Arzneimittelforschung 32:1256–1259
Maj J, Sowinska H, Baran L, Sarnek J (1974) Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative. Eur J Pharmacol 26:9–14
McLean MJ, Dettbarn W-D, Gupta RC (1987) Anticonvulsant properties of memantine. Neurology 37:350–351
McNamara JO (1986) Kindling model of epilepsy. In: Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ (eds) Basic Mechanisms of the Epilepsies. Molecular and Cellular Approaches. Raven Press, New York p 303–318
Meldrum BS, Turski L, Schwarz M, Czuczwar SJ, Sontag K-H (1986) Anticonvulsant action of 1,3-dimethyl-5-aminoadamantane. Pharmacological studies in rodents and baboon, Papio papio. Naunyn-Schmiedeberg's Arch Pharmacol 332:93–97
Miltner FO (1982a) Wertigkeit der symptomatischen Therapie mit Memantin beim zerebralen Koma. 1. Korrelation von Komastadien und EEG-Spektralverldufen. Arzneimittelforschung 32:1268–1270
Miltner FO (1982b) Wertigkeit der symptomatischen Therapie mit Memantin beim zerebralen Koma. II. Verlaufsentwicklung der Strecksynergismen beim Koma mit Hirnstammsymptomatik. Arzneimittelforschung 32:1271–1273
Mody I, Heinemann U (1987) NMDA receptors of dentate gyrus granule cells participate in synaptic transmission following kindling. Nature 326:701–704
Morimoto K, Goddard GV (1986) Kindling induced changes in the EEG recorded during stimulation from the site of stimulation: collapse of GABA-mediated inhibition of onset of rhythmic synchronous burst. Exp Neurol 94:571–584
Myslobosky MS, Golovchinski V, Mintz M (1981) Ketamine: convulsant or anticonvulsant? Pharmacol Biochem Behav 14:27–33
Netzer R, Koch R, Bigalke H (1988) Memantine: electrophysiological evidence from spinal cord neurones in vitro for an anticonvulsant action. Naunyn-Schmiedeberg's Arch Pharmacol 337 (Suppl): R115
Netzer R, Lampe H, Binschek T (1989) Anticonvulsant drugs alter bursting activities in cultured neurons by various modes of action. Naunyn-Schmiedeberg's Arch Pharmacol 339 (Suppl): R112
Osborne NN, Beale R, Golembiowska-Nikitin K, Sontag K-H (1982) The effect of memantine on various neurobiological processes. Arzneimittelforschung 32:1246–1255
Paul SM, Skolnick P (1978) Rapid changes in brain benzodiazepine receptors after experimental seizures. Science 202:892–893
Pinel JPJ, Cheung KF (1977) Controlled demonstration of metrazol kindling. Pharmacol Biochem Behav 6:599–600
Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32:281–294
Schneider E, Fischer P-A, Clemens R, Balzereit F, Fünfgeld E-W, Haase HJ (1984) Effects of oral memantine on symptoms of Parkinson's disease. Dtsch Med Wochenschr 109:987–992
Svensson TH (1973) Dopamine release and direct dopamine receptor activation in the central nervous system by D-145, an amantadine derivative. Eur J Pharmacol 23:232–238
Wagner L, Klee MR, Zeise M (1989) Different and dose-dependent actions of memantine on hippocampal neurons. Comparison with actions known from classical anticonvulsant drugs. Exp Brain Res (in press)
Author information
Authors and Affiliations
Additional information
Send offprint requests to W. Löscher at the above address
Rights and permissions
About this article
Cite this article
Löscher, W., Hönack, D. High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats. Naunyn-Schmiedeberg's Arch Pharmacol 341, 476–481 (1990). https://doi.org/10.1007/BF00176343
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00176343